<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548258" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548258/" /><meta name="ncbi_pagename" content="Ceftriaxone - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Ceftriaxone - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Ceftriaxone" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2014/05/05" /><meta name="citation_pmid" content="31643582" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548258/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Ceftriaxone" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2014/05/05" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548258/" /><meta name="description" content="Ceftriaxone is a third generation cephalosporin antibiotic which has been associated with development of biliary sludge and biliary colic when given parenterally and in high doses. Ceftriaxone is also associated with rare instances of immunoallergic, usually cholestatic hepatitis similar to the injury associated with other cephalosporins." /><meta name="og:title" content="Ceftriaxone" /><meta name="og:type" content="book" /><meta name="og:description" content="Ceftriaxone is a third generation cephalosporin antibiotic which has been associated with development of biliary sludge and biliary colic when given parenterally and in high doses. Ceftriaxone is also associated with rare instances of immunoallergic, usually cholestatic hepatitis similar to the injury associated with other cephalosporins." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548258/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Ceftriaxone/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548258/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8B31B104669E010000000003CA011A.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548258_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548258_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/CatsClaw/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Celandine/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548258_"><span class="title" itemprop="name">Ceftriaxone</span></h1><p class="small">Last Update: <span itemprop="dateModified">May 5, 2014</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Ceftriaxone.OVERVIEW"><h2 id="_Ceftriaxone_OVERVIEW_">OVERVIEW</h2><div id="Ceftriaxone.Introduction"><h3>Introduction</h3><p>Ceftriaxone is a third generation cephalosporin antibiotic which has been associated with development of biliary sludge and biliary colic when given parenterally and in high doses. Ceftriaxone is also associated with rare instances of immunoallergic, usually cholestatic hepatitis similar to the injury associated with other cephalosporins.</p></div><div id="Ceftriaxone.Background"><h3>Background</h3><p>Ceftriaxone (sef" trye ax' one) is a third generation cephalosporin was was approved for use in the United States in 1984, and it continues to be widely used. Ceftriaxone is available in a parenteral formulation generically and under the brand name of Rocephin. It can be given either intravenously or intramuscularly and is indicated for therapy of moderate-to-severe bacterial infections caused by susceptible organisms. Typical dose regimens in adults are 1 to 2 grams given im or iv in one or two divided doses daily for 7 to 14 days. The parenteral cephalosporins are widely used in medicine for serious infections and can be safely given to patients with advanced liver disease, dose modifications being required mainly for renal insufficiency. Ceftriaxone is also approved for use in children.</p></div><div id="Ceftriaxone.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Parenteral administration of ceftriaxone has been associated with development of biliary sludge in 3% to 46% of patients. The incidence may be higher in children than adults and is associated with higher doses and longer courses of treatment and possibly with fasting or dehydration. The syndrome is referred to as &#x0201c;pseudo-lithiasis&#x0201d; as the sludge and stones consist largely of ceftriaxone and they resolve spontaneously when the drug is stopped, indicating that surgery can be avoided. Most cases occur with minimal or no symptoms. Frank symptoms of cholecystitis are reported in up to 5% of patients who develop pseudo-lithiasis. Typically, serum enzymes and bilirubin levels remain normal even with biliary colic, but in rare instances there is cholestatic jaundice or gallstone pancreatitis that can be severe and require surgical intervention. Sludge and symptoms of gallbladder disease can arise within a few days of starting therapy, but typically resolve rapidly once ceftriaxone is stopped, although sludge and gallstones may be detectable by ultrasound for several months.</p><p>Ceftriaxone can also lead to an immunoallergic form of cholestatic hepatitis similar to what has been described with other cephalosporins. This reaction is idiosyncratic and is very rare. Symptoms of abdominal pain, nausea, pruritis and jaundice arise within 1 to 4 weeks of initiation of therapy and may worsen for 1 to 2 weeks after stopping the antibiotic. A cholestatic pattern of serum enzyme elevations and immunoallergic features of fever, rash and eosinophilia are common. The injury is usually mild and self-limited.</p></div><div id="Ceftriaxone.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The mechanism of biliary sludge formation during ceftriaxone therapy appears to be the propensity of ceftriaxone to bind calcium and form insoluble crystals in bile in the gallbladder, resulting in biliary sludge or frank stones. This complication is not idiosyncratic, being demonstrable in animal models. In a similar manner, calcium salts of ceftriaxone can precipitate in urine and lead to sludge in ureters or bladder that are capable of causing urinary obstruction or symptomatic kidney and bladder stones. The rare, idiosyncratic acute cholestatic liver injury linked to ceftriaxone is probably due to hypersensitivity.</p></div><div id="Ceftriaxone.Outcome_and_Management"><h3>Outcome and Management</h3><p>In most case reports, recovery has been rapid within 1 to 2 weeks, but some patients have required cholecystectomy during the acute illness and stones or sludge may persist for up to several months. The immunoallergic form of cholestatic hepatitis generally resolves rapidly and has not been associated with acute liver failure or chronic injury.</p><p>Drug Class: Antiinfective Agents, <a href="/books/n/livertox/Cephalosporins/">Cephalosporins</a></p></div></div><div id="Ceftriaxone.CASE_REPORT"><h2 id="_Ceftriaxone_CASE_REPORT_">CASE REPORT</h2><div id="Ceftriaxone.Case_1._Biliary_sludge_and_c"><h3>Case 1. Biliary sludge and cholestatic hepatitis during intravenous administration of ceftriaxone.</h3><p>[Modified from: Zinberg J, Chernaik R, Coman E, Rosenblatt R, Brandt LJ. Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis. Am J Gastro 1991; 86: 1251-4. <a href="https://www.ncbi.nlm.nih.gov/pubmed/1882806" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed Citation</a>].</p><p>A 73 year old woman with rheumatoid arthritis developed nausea and right upper quadrant pain on the twelfth day of therapy with iv ceftriaxone for Klebsiella sepsis. A DISIDA scan demonstrated nonvisualization of the gallbladder and no excretion after 4 hours, suggesting common bile duct obstruction. Serum enzymes and amylase levels, which had been normal on admission, were increased. Abdominal ultrasound showed multiple small calculi in the gallbladder, but no biliary dilatation. Ultrasound done early during the hospitalization (for evaluation of renal disease) had shown a normal gallbladder without stones. Ceftriaxone was stopped a few days later and her abdominal pain and nausea improved promptly. Four days later, amylase and <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> levels were normal. Four weeks later, ultrasound demonstrated disappearance of the gallstones and alkaline phosphatase levels were normal.</p><div id="Ceftriaxone.Key_Points"><h4>Key Points</h4><div id="Ceftriaxone.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548258/table/Ceftriaxone.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Ceftriaxone.T1_lrgtbl__"><table><thead><tr><th id="hd_h_Ceftriaxone.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Medication:</th><td rowspan="1" colspan="1" style="vertical-align:top;">Ceftriaxone, 1.0 gram iv every 12 hours for 14 days</td></tr></thead><tbody><tr><th headers="hd_h_Ceftriaxone.T1_1_1_1_1" id="hd_b_Ceftriaxone.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Pattern:</th><td headers="hd_b_Ceftriaxone.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Cholestatic (R=1.7)</td></tr><tr><th headers="hd_h_Ceftriaxone.T1_1_1_1_1" id="hd_b_Ceftriaxone.T1_1_1_2_1" rowspan="1" colspan="1" style="vertical-align:top;">Severity:</th><td headers="hd_b_Ceftriaxone.T1_1_1_2_1" rowspan="1" colspan="1" style="vertical-align:top;">1+ (no jaundice)</td></tr><tr><th headers="hd_h_Ceftriaxone.T1_1_1_1_1" id="hd_b_Ceftriaxone.T1_1_1_3_1" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Ceftriaxone.T1_1_1_3_1" rowspan="1" colspan="1" style="vertical-align:top;">Twelve days</td></tr><tr><th headers="hd_h_Ceftriaxone.T1_1_1_1_1" id="hd_b_Ceftriaxone.T1_1_1_4_1" rowspan="1" colspan="1" style="vertical-align:top;">Recovery:</th><td headers="hd_b_Ceftriaxone.T1_1_1_4_1" rowspan="1" colspan="1" style="vertical-align:top;">Complete in 4 weeks</td></tr><tr><th headers="hd_h_Ceftriaxone.T1_1_1_1_1" id="hd_b_Ceftriaxone.T1_1_1_5_1" rowspan="1" colspan="1" style="vertical-align:top;">Other medications:</th><td headers="hd_b_Ceftriaxone.T1_1_1_5_1" rowspan="1" colspan="1" style="vertical-align:top;">Piroxicam, ranitidine, furosemide, thyroxine, vitamin D, calcium</td></tr></tbody></table></div></div></div><div id="Ceftriaxone.Laboratory_Values"><h4>Laboratory Values</h4><div id="Ceftriaxone.T2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548258/table/Ceftriaxone.T2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Ceftriaxone.T2_lrgtbl__"><table><thead><tr><th id="hd_h_Ceftriaxone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Time After Starting</th><th id="hd_h_Ceftriaxone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Time After Stopping</th><th id="hd_h_Ceftriaxone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> (U/L)</th><th id="hd_h_Ceftriaxone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Alk P (U/L)</th><th id="hd_h_Ceftriaxone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a> (mg/dL)</th><th id="hd_h_Ceftriaxone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Ceftriaxone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Pre</td><td headers="hd_h_Ceftriaxone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Ceftriaxone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">51</td><td headers="hd_h_Ceftriaxone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">103</td><td headers="hd_h_Ceftriaxone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.2</td><td headers="hd_h_Ceftriaxone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Admission for GI bleeding</td></tr><tr><td headers="hd_h_Ceftriaxone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Ceftriaxone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Ceftriaxone.T2_1_1_1_3 hd_h_Ceftriaxone.T2_1_1_1_4 hd_h_Ceftriaxone.T2_1_1_1_5 hd_h_Ceftriaxone.T2_1_1_1_6" colspan="4" rowspan="1" style="vertical-align:top;">Ceftriaxone started (day 7 of hospitalization)</td></tr><tr><td headers="hd_h_Ceftriaxone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">12 days</td><td headers="hd_h_Ceftriaxone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Ceftriaxone.T2_1_1_1_3 hd_h_Ceftriaxone.T2_1_1_1_4 hd_h_Ceftriaxone.T2_1_1_1_5 hd_h_Ceftriaxone.T2_1_1_1_6" colspan="4" rowspan="1" style="vertical-align:top;">Abdominal pain and nausea: gallbladder sludge</td></tr><tr><td headers="hd_h_Ceftriaxone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">13 days</td><td headers="hd_h_Ceftriaxone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Ceftriaxone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">92</td><td headers="hd_h_Ceftriaxone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">183</td><td headers="hd_h_Ceftriaxone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.4</td><td headers="hd_h_Ceftriaxone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Amylase 513</td></tr><tr><td headers="hd_h_Ceftriaxone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">14 days</td><td headers="hd_h_Ceftriaxone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Ceftriaxone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">252</td><td headers="hd_h_Ceftriaxone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">299</td><td headers="hd_h_Ceftriaxone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Ceftriaxone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Ceftriaxone stopped</td></tr><tr><td headers="hd_h_Ceftriaxone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">18 days</td><td headers="hd_h_Ceftriaxone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">4 days</td><td headers="hd_h_Ceftriaxone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">52</td><td headers="hd_h_Ceftriaxone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">245</td><td headers="hd_h_Ceftriaxone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Ceftriaxone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Ultrasound: single gallstone</td></tr><tr><td headers="hd_h_Ceftriaxone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">6 weeks</td><td headers="hd_h_Ceftriaxone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">4 weeks</td><td headers="hd_h_Ceftriaxone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Ceftriaxone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Ceftriaxone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Ceftriaxone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Ultrasound: no gallstones</td></tr><tr><td headers="hd_h_Ceftriaxone.T2_1_1_1_1 hd_h_Ceftriaxone.T2_1_1_1_2" colspan="2" rowspan="1" style="vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Ceftriaxone.T2_1_1_1_3 hd_h_Ceftriaxone.T2_1_1_1_4" colspan="2" rowspan="1" style="vertical-align:top;"><b>Not given</b></td><td headers="hd_h_Ceftriaxone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Ceftriaxone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr></tbody></table></div></div></div><div id="Ceftriaxone.Comment"><h4>Comment</h4><p>Only 5% to 10% of patients who develop biliary sludge (pseudolithiasis) during ceftriaxone therapy develop symptoms of biliary colic and, even with symptoms, patients rarely develop elevations of serum enzymes or bilirubin levels. The case described above developed what appeared to be a gallstone pancreatitis and partial biliary obstruction leading to mild elevations in serum aminotransferase and alkaline phosphatase levels, but without jaundice. The development of ceftriaxone biliary stones during therapy and dissolution afterwards was nicely documented in this case report. The biliary symptoms resolved with a day or two and the stones within 4 weeks of stopping therapy.</p></div></div></div><div id="Ceftriaxone.PRODUCT_INFORMATION"><h2 id="_Ceftriaxone_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><div id="Ceftriaxone.BPI" class="box"><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Ceftriaxone &#x02013; Generic, Rocephin&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antiinfective Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Ceftriaxone" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></div><div id="Ceftriaxone.CHEMICAL_FORMULA_AND_STRUCTU"><h2 id="_Ceftriaxone_CHEMICAL_FORMULA_AND_STRUCTU_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Ceftriaxone.T3" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548258/table/Ceftriaxone.T3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Ceftriaxone.T3_lrgtbl__"><table><thead><tr><th id="hd_h_Ceftriaxone.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">DRUG</th><th id="hd_h_Ceftriaxone.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">CAS REGISTRY NO</th><th id="hd_h_Ceftriaxone.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Ceftriaxone.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Ceftriaxone.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Ceftriaxone Sodium</td><td headers="hd_h_Ceftriaxone.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135010859" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">74578-69-1</a></td><td headers="hd_h_Ceftriaxone.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C18-H18-N8-O7-S3.2Na</td><td headers="hd_h_Ceftriaxone.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><div class="graphic"><img src="/books/NBK548258/bin/Ceftriaxone_Structure.jpg" alt="Ceftriaxone sodium chemical structure" /></div></td></tr></tbody></table></div></div></div><div id="Ceftriaxone.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Ceftriaxone_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 05 May 2014</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Ceftriaxone.R1">Zimmerman HJ. Cephalosporins. In, Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd Ed. Philadelphia: Lippincott, 1999. p. 589-92.<div><i>(Expert review of cephalosporins and liver injury published in 1999).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R2">Moseley RH. Hepatotoxicity of antimicrobials and antifungal agents. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013. p. 463-83.<div><i>(Review of cephalosporin induced liver injury mentions that ceftriaxone has been linked to biliary sludge and concretions and with occasional reports of cholestatic hepatitis).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R3">Petri WA Jr. Penicillins, cephalosporins, and other &#x000df;-lactam antibiotics. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman's The pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill, 2011: 1477-1504.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R4">File TM Jr, Tan JS, Salstrom SJ. Clinical evaluation of ceftriaxone. Clin Ther 1984; 6: 653-61.  [<a href="/pubmed/6090021" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6090021</span></a>]<div><i>(Analysis of 77 patients receiving ceftriaxone for serious infections; 93% efficacy; ALT elevations in 8 [10%, peak levels 92 U/L] ).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R5">Oakes M, MacDonald H, Wilson D. Abnormal laboratory test values during ceftriaxone therapy. Am J Med 1984; 77: 89-96.  [<a href="/pubmed/6093527" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6093527</span></a>]<div><i>(Analysis of laboratory test abnormalities among 2640 patients receiving ceftriaxone for 1 day to 6 weeks at varying doses in prelicensure studies; ALT elevations occurred in 3.1%, Alk P 1.0% and bilirubin in 0.3%; rates that were similar to those of other iv cephalosporins; one case had ALT elevations with jaundice which resolved ultimately, but was not otherwise characterized).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R6">Moskovitz BL. Clinical adverse effects during ceftriaxone therapy. Am J Med 1984; 77 (4C): 84-8.  [<a href="/pubmed/6093526" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6093526</span></a>]<div><i>(Review of adverse effects of ceftriazone in pre-licensure studies; 2640 patients in 153 studies, allergic reactions in 3%; jaundice in 2 patients, both of whom were septic and resolved with stopping therapy; no mention of biliary cholic).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R7">Parry MF. Toxic and adverse reactions encountered with new beta-lactam antibiotics. Bull N Y Acad Med 1984; 60: 358-68.  [<a href="/pmc/articles/PMC1911778/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1911778</span></a>] [<a href="/pubmed/6586251" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6586251</span></a>]<div><i>(Review suggesting that hepatitis occurs in "2-5%" of cephalosporin- and penicillin treated patients).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R8">Barson WJ, Miller MA, Brady MT, Powell DA. Prospective comparative trial of ceftriaxone vs. conventional therapy for treatment of bacterial meningitis in children. Pediatr Infect Dis 1985; 4: 362-8.  [<a href="/pubmed/3895175" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3895175</span></a>]<div><i>(Trial comparing ceftriaxone to ampicillin with chloramphenicol for meningitis in 50 children; similar efficacy, more diarrhea with ceftriaxone and 11% had minor ALT elevations, returning to normal during or after therapy).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R9">Schaad UB, Tsch&#x000e4;ppeler H, Lentze MJ. Transient formation of precipitations in the gallbladder associated with ceftriaxone therapy. Pediatr Infect Dis J 1986; 5: 708-10.  [<a href="/pubmed/3540889" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3540889</span></a>]<div><i>(Initial report of transient biliary sludge in a 18 year old male with chronic granulomatous disease receiving iv ceftriaxone, who was found to have gallbladder abnormalities incidentally while being followed for a splenic abscess with repeat ultrasound examinations; the stones appeared during therapy and resolved soon after ceftriaxone was stopped).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R10">Norrby SR. Side effects of cephalosporins. Drugs 1987; 34 (Suppl 2): 105-20.  [<a href="/pubmed/3319495" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3319495</span></a>]<div><i>(Clinical review of cephalosporins: ALT elevations occur in 1-8% of treated patients, but clinically apparent hepatitis is rare, usually occurring with allergic symptoms; little evidence for cross hypersensitivity with penicillins).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R11">Schaad UB, Wedgwood-Krucko J, Tsch&#x000e4;ppeler H. Reversible ceftriaxone-associated biliary pseudolithiasis in children. Lancet 1988; 2: 1411-3.  [<a href="/pubmed/2904533" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2904533</span></a>]<div><i>(Prospective ultrasound study of 37 children receiving ceftriaxone; 16 [43%] developed sludge and 1 urolithiasis in 4 to 22 days, 3 [8%] symptomatic, all resolved in 2-63 days; referred to syndrome as "biliary pseudolithiasis").</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R12">Jacobs RF. Ceftriaxone-associated cholecystitis. Pediatr Infect Dis J 1988; 7: 434-6.  [<a href="/pubmed/3293002" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3293002</span></a>]<div><i>(16 year old girl given 2 g ceftriaxone iv twice daily, and 3 days later developed biliary colic with raised GGT [184 U/L], resolved in 8 weeks).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R13">Meyboom RH, Kuiper H, Jansen A. Ceftriaxone and reversible cholelithiasis. BMJ 1988; 297: 858.  [<a href="/pmc/articles/PMC1834624/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1834624</span></a>] [<a href="/pubmed/3140956" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3140956</span></a>]<div><i>(Two cases of biliary colic in adults during ceftriaxone therapy, both resolved; cholecystectomy later in one showed no stones and no abnormalities of gallbladder).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R14">Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM. Ceftriaxone-associated biliary pseudolithiasis in adults. Lancet 1989; 2: 165.  [<a href="/pubmed/2567936" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2567936</span></a>]<div><i>(Prospective ultrasound study in 20 adults receiving iv ceftriaxone; 5 [25%] developed stones by 4-17 days, all resolving in 7-26 days, serum enzymes normal and no symptoms; stones correlated with total ceftriaxone dose [5-80 g]).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R15">Cometta A, Gallot-Lavall&#x000e9;e-Villars S, Iten A, Cantoni L, Anderegg A, Convers JJ, Glauser MP. Incidence of gallbladder lithiasis after ceftriaxone treatment. J Antimicrob Chemother 1990; 25: 689-95.  [<a href="/pubmed/2190975" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2190975</span></a>]<div><i>(Prospective study of 34 patients given amoxicillin/clavulanate vs 40 given ceftriaxone; follow up 6 and 12 months later showed only one gallstone - in an amoxicillin/clavulanate treated patient; ultrasound not done during therapy).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R16">Heim-Duthoy KL, Caperton EM, Pollock R, Matzke GR, Enthoven D, Peterson PK. Apparent biliary pseudolithiasis during ceftriaxone therapy. Antimicrob Agents Chemother 1990; 34: 1146-9.  [<a href="/pmc/articles/PMC171774/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC171774</span></a>] [<a href="/pubmed/2203305" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2203305</span></a>]<div><i>(Prospective study in 28 adults on iv ceftriaxone and 8 controls for 14 days found abnormalities in 6 [21%] treated and 1 [12%] controls after 14 days; 2 were symptomatic, all resolved spontaneously within 9 to 26 days).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R17">Shiffman ML, Keith FB, Moore EW. Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology 1990; 99: 1772-8.  [<a href="/pubmed/2227290" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2227290</span></a>]<div><i>(Ceftriaxone binds calcium in vitro and forms precipitations when added at high concentrations to human bile).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R18">Schaad UB, Suter S, Gianella-Borradori A, Pfenninger J, Auckenthaler R, Bernath O, Cheseaux JJ, et al. A comparison of ceftriaxone and cefuroxime for treatment of bacterial meningitis in children. N Engl J Med 1990; 322: 141-7.  [<a href="/pubmed/2403654" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2403654</span></a>]<div><i>(Prospective study comparing ceftriaxone and cefuroxime in 106 children with meningitis; all were cured; ultrasound identified sludge in 16 of 35 treated with ceftriaxone, but none in 35 cefuroxime treated children after 3-10 days; sludge resolved completely in 11 to 63 days after therapy; 3 [9%] had colic).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R19">Fekety FR. Safety of parenteral third-generation cephalosporins. Am J Med 1990; 88 (Suppl 4A): 38S-44S.  [<a href="/pubmed/2183609" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2183609</span></a>]<div><i>(Review article stating that aminotransferase elevations can occur on cephalosporin therapy, but clinically apparent liver disease is rare).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R20">Lopez AJ, O'Keefe P, Morrissey M, Pickleman J. Ceftriaxone-induced cholelithiasis. Ann Intern Med 1991; 115: 712-14.  [<a href="/pubmed/1929040" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1929040</span></a>]<div><i>(Patient on iv ceftriaxone for endocarditis for unclear period of time developed pancreatitis and later underwent cholecystectomy demonstrating five soft, green ceftriaxone stones).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R21">Zinberg J, Chernaik R, Coman E, Rosenblatt R, Brandt LJ. Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis. Am J Gastroenterol 1991; 86: 1251-4.  [<a href="/pubmed/1882806" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1882806</span></a>]<div><i>(73 year old woman with multiple medical problems developed biliary colic and pancreatitis [peak amylase 513 U/L] after 12 days of iv ceftriaxone for Klebsiella sepsis, with mild elevations in Alk P [299 U/L] and ALT [252 U/L], but no jaundice, resolving once ceftriaxone was stopped: Case 1).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R22">Park HZ, Lee SP, Schy AL. Ceftriaxone-associated gallbladder sludge. Identification of calcium-ceftriaxone salt as a major component of gallbladder precipitate. Gastroenterology 1991; 100: 1665-70.  [<a href="/pubmed/2019372" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2019372</span></a>]<div><i>(Surgical specimens from 4 patients with biliary sludge after ceftriaxone therapy showed no stones, but rather granular-crystalline material of cholesterol [2%], bilirubin [14%] and calcium-ceftriaxone).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R23">Kim YS, Kestell MR, Lee SP. Gall-bladder sludge: lessons from ceftriaxone. J Gastroenterol Hepatol 1992; 7: 618-21.  [<a href="/pubmed/1486190" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1486190</span></a>]<div><i>(Review and discussion of pathogenesis of ceftriaxone associated biliary sludge and stone formation).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R24">Riccabona M, Kerbl R, Schwinger W, Spork D, Millner M, Grubbauer HM. [Ceftriaxone-induced cholestasis - a harmless side-effect?]. Klin Padiatr 1993; 205: 421-3. German.  [<a href="/pubmed/8309205" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8309205</span></a>]<div><i>(Among 43 children receiving iv ceftriaxone, 20 developed sludge by ultrasound within 10 days, 2 developing serum enzyme abnormalities, another 3 had severe pain, but all resolved within 2 months).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R25">Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB. Disappearing &#x0201c;gallstones&#x0201d;: biliary pseudolithiasis complicating ceftriaxone therapy. AJR Am J Roentgenol 1992; 159: 329-30.  [<a href="/pubmed/1632349" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1632349</span></a>]<div><i>(19 year old woman with Lyme disease developed biliary colic 1 week after starting a 14 day course of iv ceftriaxone; had symptoms of fever and colic with gallstones on ultrasound that resolved in the next 3 weeks without therapy).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R26">Michielsen PP, Fierens H, Van Maercke YM. Drug-induced gallbladder disease. Incidence, aetiology and management. Drug Saf 1992; 7: 32-45.  [<a href="/pubmed/1536697" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1536697</span></a>]<div><i>(Review article on drug induced gallbladder disease focusing upon estrogens, clofibrate, ceftriaxone, octreotide, and hepatic artery chemotherapy).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R27">Thompson JW, Jacobs RF. Adverse effects of newer cephalosporins. An update. Drug Saf 1993; 9: 132-142.  [<a href="/pubmed/8397890" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8397890</span></a>]<div><i>(Extensive review; transient increases in ALT, AST or Alk P have been reported in 0.7%, 6%, 11% and 28% of prospectively followed patients treated with various cephalosporins; clinically significant biliary sludging with ceftriaxone, particularly in children, not found with other cephalosporins).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R28">Blais C, Duperval R. Biliary pseudolithiasis in a child associated with 2 days of ceftriaxone therapy. Pediatr Radiol 1994; 24: 218-9.  [<a href="/pubmed/7936805" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7936805</span></a>]<div><i>(18 month old boy given iv ceftriaxone for 2 days, developed biliary colic on day 5, normal gallbladder and no stones found on cholecystectomy on day 11).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R29">Barzilai M. [Sonographic demonstration of pseudo-cholelithiasis after ceftriaxone] Harefuah 1994; 127: 163-5. Hebrew.  [<a href="/pubmed/7995584" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7995584</span></a>]<div><i>(Case series of 2 children who developed symptoms and gallbladder sludge on ceftriaxone therapy; resolved with discontinuation).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R30">Di Martino V, Cadranel JF, Attali P. [Hepatobiliary complications induced by cephalosporins] Gastroenterol Clin Biol 1994; 18: 839-46. French.  [<a href="/pubmed/7875391" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7875391</span></a>]<div><i>(Review of hepatobiliary complications of cephalosporins mentioning rare case reports of hepatotoxicity and issue of pseudolithiasis with ceftriaxone).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R31">Ettestad PJ, Campbell GL, Welbel SF, et al. Biliary complications in the treatment of unsubstantiated Lyme disease. J Infect Dis 1995; 171: 356-61.  [<a href="/pubmed/7844372" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7844372</span></a>]<div><i>(Case control study in a hospital that reported 1730 admissions for therapy of Lyme disease; among 1352 patients, 24 developed gallstone disease and 14 had cholecystectomy; all had received iv ceftriaxone).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R32">Stabile A, Ferrara P, Marietti G, Maresca G. Ceftriaxone-associated gallbladder lithiasis in children. Eur J Pediatr 1995; 154: 590.  [<a href="/pubmed/7556332" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7556332</span></a>]<div><i>(Prospective study of 41 children receiving iv ceftriaxone; 5 [12%] developed stones/sludge, one with symptoms, all resolved in 10-30 days).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R33">Benedetti M, Zanchetta S, Bagnani A, Praderio R, Perbellini S, Melo C. [Pseudolithiasis caused by ceftriaxone in children: a case report] Pediatr Med Chir 1995; 17: 369-71. Italian.  [<a href="/pubmed/7491336" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7491336</span></a>]<div><i>(1 year old child developed symptomatic pseudolithiasis during iv ceftriaxone therapy, which resolved within 4 weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R34">George DK, Crawford DH. Antibacterial-induced hepatotoxicity. Incidence, prevention and management. Drug Saf 1996; 15: 79-85.  [<a href="/pubmed/8862966" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8862966</span></a>]<div><i>(Review of hepatotoxicity from antibiotics with one sentence on cephalosporins, describing liver injury from this class as being extremely rare, although elevations in aminotransferases occurred in 0.7-11% of treated patients).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R35">Robertson FM, Crombleholme TM, Barlow SE, Verhave M, Brown D. Ceftriaxone choledocholithiasis. Pediatrics 1996; 98: 133-5.  [<a href="/pubmed/8668387" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8668387</span></a>]<div><i>(9 year old boy given 7 day course of iv ceftriaxone, developed biliary colic 5 days later, abnormal Alk P [335 U/L] and biliary dilatation on ultrasound; surgery found ceftriaxone stone in common bile duct).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R36">Kong MS, Chen CY. Risk factors leading to ceftriaxone-associated biliary pseudolithiasis in children. Changgeng Yi Xue Za Zhi. 1996; 19: 50-4.  [<a href="/pubmed/8935375" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8935375</span></a>]<div><i>(Prospective ultrasound study in 151 children receiving iv ceftriaxone; 5 [3%] developed asymptomatic pseudolithiasis after 3-7 days; risk factors were fasting and older age).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R37">Longo F, Hastier P, Buckley MJ, Chichmanian RM, Delmont JP. Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone. Am J Gastroenterol 1998; 93: 836-7.  [<a href="/pubmed/9625142" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9625142</span></a>]<div><i>(Elderly man developed jaundice with mixed enzyme elevations 3 days after a 12 day course of oral ceftriaxone; bilirubin 22 times, ALT 11 times and Alk P 6 times ULN, later developed severe hemolytic anemia requiring prednisone and resolving only by six months).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R38">Maranan MC, Gerber SI, Miller GG. Gallstone pancreatitis caused by ceftriaxone. Pediatr Infect Disease J 1998; 17: 662-3.  [<a href="/pubmed/9686742" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9686742</span></a>]<div><i>(13 year old developed pancreatitis 4 days after stopping 5 weeks of ceftriaxone with several other antibiotics; amylase 1133 U/L but normal ALT. Cholecystectomy showed stones and chronic cholecystitis; analysis of stone showed "100%"ceftriaxone).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R39">Herek O, Sario&#x00026;#287lu A, Ko&#x000e7;er N, Tiryaki A, Akkemik B. Biliary pseudolithiasis in childhood: a case report. Eur J Pediatr Surg 1999; 9: 337-9.  [<a href="/pubmed/10584197" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10584197</span></a>]<div><i>(Case report of symptomatic biliary sludge arising after 6 days of intravenous ceftriaxone, resolving within 11 days of stopping).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R40">Vega C, Quinby PM, Aspy CB. Hepato-biliary abnormalities secondary to ceftriaxone use: a case report. J Okla State Med Assoc 1999; 92: 432-4.  [<a href="/pubmed/10461415" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10461415</span></a>]<div><i>(10 month old with rotavirus infection given ceftriaxone developed elevated Alk P [3580 U/L] and AST [84 U/L] after ~7 days, normal gallbladder ultrasound, rapid recovery).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R41">Papadopoulos F, Efremidis S, Karyda S, Badouraki M, Karatza E, Panteliadis C, Malaka K. Incidence of ceftriaxone-associated gallbladder pseudolithiasis. Acta Paediatr 1999; 88: 1352-5.  [<a href="/pubmed/10626521" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10626521</span></a>]<div><i>(Prospective study in 44 children given iv ceftriaxone for 3 to 14 days; 11 [25%] developed pseudolithiasis after 2-9 days, 2 with symptoms [5%]; all resolved completely in 8-23 days).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R42">de Moor RA, Egberts AC, Schr&#x000f6;der CH. Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis. Eur J Pediatr 1999; 158: 975-7.  [<a href="/pubmed/10592073" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10592073</span></a>]<div><i>(7 year old boy developed urinary stone and biliary sludge after 4 days of high dose iv ceftriaxone and passed a ceftriaxone containing urinary stone after 10 days).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R43">Bonnet JP, Abid L, Dabhar A, L&#x000e9;vy A, Soulier Y, Blangy S. Early biliary pseudolithiasis during ceftriaxone therapy for acute pyelonephritis in children: a prospective study in 34 children. Eur J Pediatr Surg 2000; 10: 368-71.  [<a href="/pubmed/11215777" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11215777</span></a>]<div><i>(Prospective study in 34 children given iv ceftriaxone with ultrasound before and at end of therapy; 5 [15%] developed asymptomatic gallstones, all resolved within 5 months).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R44">Tuckuviene R, Myrtue GS. [Symptomatic pseudolithiasis caused by Rocephalin]. Ugeskr Laeger 2000; 162: 4271-2. Danish.  [<a href="/pubmed/10962947" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10962947</span></a>]<div><i>(5 year old girl developed symptomatic pseudolithiasis on ceftriaxone, resolving rapidly with stopping).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R45">Palanduz A, Yal&#x000e7;in I, Tongu&#x000e7; E, et al. Sonographic assessment of ceftriaxone-associated biliary pseudolithiasis in children. J Clin Ultrasound 2000; 28: 166-8.  [<a href="/pubmed/10751736" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10751736</span></a>]<div><i>(Prospective study of 118 children receiving 1-3 weeks of iv ceftriaxone found 17% developed sludge; all were asymptomatic and all resolved in 2 weeks; no risk factors observed).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R46">Grasberger H, Otto B, Loeschke K. Cefriaxone-associated nephrolithiasis. Ann Pharmacother 2000; 34: 1076-7.  [<a href="/pubmed/10981257" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10981257</span></a>]<div><i>(31 year old man developed symptomatic kidney stones 8 days after starting iv ceftriaxone, resolving spontaneously).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R47">Prince JS, Senac MO Jr. Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis in a child. Pediatr Radiol 2003; 33: 648-51.  [<a href="/pubmed/12830336" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12830336</span></a>]<div><i>(14 year old boy developed nephrolithiasis with pain and hematuria and increased creatinine; both biliary and urinary sludge found, referred to as "toothpaste"; resolution in 3 weeks).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R48">Ravisha MS, Godambe SV. Ceftriaxone induced cholestasis in a neonate: a case report. Indian J Med Sci 2004; 58: 73-4.  [<a href="/pubmed/14993721" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14993721</span></a>]<div><i>(17 day old male developed cholestasis after 7 days of iv ceftriaxone; sludge on ultrasound, bilirubin 2.6 mg/dL, ALT 98 U/L, Alk P 1194 U/L, resolution within 3-7 days).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R49">Wen HH, Huang YK, Zheng GL. Ceftriaxone-associated gallbladder pseudolithiasis: report of one case. Acta Paediatr Taiwan 2004; 45: 290-2.  [<a href="/pubmed/15868813" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15868813</span></a>]<div><i>(5 year old boy developed cholelithiasis 5 days after starting ceftriaxone, resolving after 1 month).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R50">Acun C, Erdem LO, Sogut A, Erdem CZ, Tomac N, Gundogdu S. Ceftriaxone-induced biliary pseudolithiasis and urinary bladder sludge. Pediatr Int 2004; 46: 368-70.  [<a href="/pubmed/15151561" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15151561</span></a>]<div><i>(5 year old girl developed biliary colic after 3 days of ceftriaxone; laboratory tests were normal, but ultrasound showed both gallbladder and urinary bladder sludge, resolving spontaneous within 12 days of stopping).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R51">Acun C, Erdem LO, S&#x000f6;&#x00026;#287&#x000f6;t A, et al. Gallbladder and urinary tract precipitations associated with ceftriaxone therapy in children: a prospective study. Ann Trop Paediatr. 2004; 24: 25-31.  [<a href="/pubmed/15005963" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15005963</span></a>]<div><i>(Prospective ultrasound study of 36 children given iv ceftriaxone for up to 14 days; 5 [14%] developed gallbladder and one [3%] urinary bladder stones, most were symptomatic, all resolved spontaneously).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R52">Avci Z, Koktener A, Uras N, et al. Nephrolithiasis associated with ceftriaxone therapy: a prospective study in 51 children. Arch Dis Child 2004; 89: 1069-72.  [<a href="/pmc/articles/PMC1719698/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1719698</span></a>] [<a href="/pubmed/15499067" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15499067</span></a>]<div><i>(Prospective study of 51 children with various infections treated with ceftriaxone iv or im for 5-10 days; nephrolithiasis found by ultrasound in 4 children [8%], all asymptomatic, 3 resolved in follow up; no risk factors found).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R53">Bor O, Dinleyici EC, Kebapci M, Aydogdu SD. Ceftriaxone-associated biliary sludge and pseudocholelithiasis during childhood: a prospective study. Pediatr Int 2004; 46: 322-4.  [<a href="/pubmed/15151550" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15151550</span></a>]<div><i>(Prospective study of 38 children receiving iv ceftriaxone; ultrasound at 10 days showed gallstones in 29% and sludge in 8%; one child had symptoms; resolution usually occurred within 1 month, but sometimes required 3).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R54">Evliyaoglu C, Kizartici T, Bademci G, Unal B, Keskil S. Ceftriaxone-induced symptomatic pseudolithiasis mimicking ICP elevation. Zentralbl Neurochir 2005; 66: 92-4.  [<a href="/pubmed/15846537" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15846537</span></a>]<div><i>(Patient developed pseudolithiasis after neurosurgery and iv ceftriaxone; made differential diagnosis difficult).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R55">Ceran C, Oztoprak I, Cankorkmaz L, Gumu&#x000e7; C, Yildiz T, Koyluoglu G. Ceftriaxone-associated biliary pseudolithiasis in paediatric surgical patients. Int J Antimicrob Agents 2005; 25: 256-9.  [<a href="/pubmed/15737522" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15737522</span></a>]<div><i>(Prospective ultrasound study of 50 children treated with ceftriaxone after surgery; 13 [26%] developed sludge or stones within 4-22 days; resolved within 3-63 days, no enzyme elevations, no risk factors found).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R56">Bell MJ, Stockwell DC, Luban NL, Shirey S, Shaak L, Ness PM, Wong ECC. Ceftriaxone-induced hemolytic anemia and hepatitis in an adolescent with hemoglobin SC disease. Pediatr Crit Care Med 2005; 6: 363-6.  [<a href="/pubmed/15857541" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15857541</span></a>]<div><i>(17 year old boy with sickle cell disease and severe hemolytic anemia given ceftriaxone developed progressive renal and hepatic failure and death; liver failure likely due to shock).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R57">Bickford CL, Spencer AP. Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: case report and review of the literature. Pharmacotherapy 2005; 25: 1389-95.  [<a href="/pubmed/16185184" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16185184</span></a>]<div><i>(Review of literature on ceftriaxone associated pseudolithiasis; case report of 53 year old man with chronic hepatitis C who developed jaundice after 7 days of iv ceftriaxone with little change in ALT or AST [bilirubin 5.8 mg/dL, ALT 41 U/L, Alk P 88 U/L], which resolved only once ceftriaxone was stopped, but role of sepsis could not be excluded).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R58">Rivkin AM. Hepatocellular enzyme elevations in a patient receiving ceftriaxone. Am J Health Syst Pharm 2005; 62: 2006-10.  [<a href="/pubmed/16174837" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16174837</span></a>]<div><i>(Case report and literature review; seriously ill 31 year old man in ICU had increase in ALT from 9 to 56 to 442 U/L, but normal Alk P and bilirubin and no symptoms after 7 days of ceftriaxone therapy, with resolution within 2 weeks of switching antibiotics).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R59">Biner B, Oner N, Celtik C, Bostancio&#x0011f;lu M, Tun&#x000e7;bilek N, G&#x000fc;zel A, Karasaliho&#x0011f;lu S. Ceftriaxone-associated biliary pseudolithiasis in children. J Clin Ultrasound 2006; 34: 217-222.  [<a href="/pubmed/16673364" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16673364</span></a>]<div><i>(Among 156 children given iv ceftriaxone who were followed prospectively with serial abdominal ultrasounds, 27 [17%] developed biliary stones or sludge and 5 [3%] became symptomatic; resolving within 10-30 days of stopping; risk factors were older age and higher doses of ceftriaxone).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R60">Araz N, Okan V, Demirci M, Araz M. Pseudolithiasis due to ceftriaxone treatment for meningitis in children: report of 8 cases. Tohoku J Exp Med 2007; 211: 285-90.  [<a href="/pubmed/17347554" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17347554</span></a>]<div><i>(Case series of 8 children with ceftriaxone induced pseudolithiasis; all resolved within 30 days).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R61">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34.  [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i>(Among 300 cases of drug induced liver disease in the US collected between 2004 and 2008, one case was attributed to ceftriaxone alone [85 year old man developed cholestatic hepatitis 3 weeks after a four day course of intravenous ceftriaxone]).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R62">Peker E, Cagan E, Dogan M. Ceftriaxone-induced toxic hepatitis. World J Gastroenterol 2009; 15: 2669-71.  [<a href="/pmc/articles/PMC2691501/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2691501</span></a>] [<a href="/pubmed/19496200" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19496200</span></a>]<div><i>(12 year old boy developed fatigue after 3 days of ceftriaxone therapy followed by jaundice [bilirubin 4.2 mg/dL, ALT 871 U/L, Alk P 143 U/L, 8% eosinophils], resolving within 10 weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R63">Ferrajolo C, Capuano A, Verhamme KM, Schuemie M, Rossi F, Stricker BH, Sturkenboom MC. Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. Br J Clin Pharmacol 2010; 70: 721-8.  [<a href="/pmc/articles/PMC2997312/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2997312</span></a>] [<a href="/pubmed/21039766" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21039766</span></a>]<div><i>(Worldwide pharmacovigilance database contained 9036 hepatic adverse drug reactions in children, 104 of which were attributed to ceftriaxone, ranking 10th in frequency and being the only cephalosporin listed).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R64">Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065-76.  [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, one of which was attributed to cefepime, but none to ceftriaxone or other cephalosporins).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R65">Kaur I, Singh J. Cholestatic hepatitis with intravenous ceftriaxone. Indian J Pharmacol 2011; 43: 474-5. doi: 21845011 . [<a href="/pmc/articles/PMC3153719/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3153719</span></a>] [<a href="/pubmed/21845011" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21845011</span></a>]<div><i>(24 year old woman developed dark urine 24 hours after starting ceftriaxone and piroxicam and 3 days later was jaundiced [bilirubin 6.5 mg/dL, ALT 164 U/L, Alk P 580 U/L], resolving within 3 weeks of stopping both drugs).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R66">Choi YY, Jung YH, Choi SM, Lee CS, Kim D, Hur KY. Gallbladder pseudolithiasis caused by ceftriaxone in young adult. J Korean Surg Soc 2011; 81:423-6.  [<a href="/pmc/articles/PMC3243861/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3243861</span></a>] [<a href="/pubmed/22200045" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22200045</span></a>]<div><i> (Two men, ages 21 and 22 years, developed gallstones found by CT scan 5 and 17 days after starting ceftriaxone without symptoms or laboratory abnormalities, resolving within 1 month of stopping).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R67">Hanata N, Imamura T, Koyama R, Koizumi Y, Tamura T, Ito J, Takeuch K. [Case report; a case of biliary pseudolithiasis associated with ceftriaxone]. Nihon Naika Gakkai Zasshi 2012; 101: 2955-7. Japanese.  [<a href="/pubmed/23214106" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23214106</span></a>]</div></li><li><div class="bk_ref" id="Ceftriaxone.R68">Bj&#x000f6;rnsson ES, Bergmann OM, Bj&#x000f6;rnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 114: 1419-25.  [<a href="/pubmed/23419359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div><i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, of which 2 were attributed to cephalosporins, one with jaundice to cephalexin and one with enzyme elevations only to ceftazidime).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R69">Rodr&#x000ed;guez Rangel DA, Pinilla Orejarena AP, Bustacara Diaz M, Henao Garc&#x000ed;a L, L&#x000f3;pez Cadena A, Montoya Camargo R, Moreno LA. [Gallstones in association with the use of ceftriaxone in children.]. An Pediatr (Barc) 2013; 80: 77-80. Spanish.  [<a href="/pubmed/23759541" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23759541</span></a>]<div><i>(Prospective study in 73 children receiving ceftriaxone, identified sludge or gallstones [4-14 mm in diameter] by ultrasound in 31 [43%], of whom 7 had symptoms, all resolving within 2 months of stopping, but one requiring surgery).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R70">Zheng FY, Xing Y, Lu S, Liu DM. [Ceftriaxone-associated biliary pseudolithiasis in a child with nephrotic syndrome]. Zhongguo Dang Dai Er Ke Za Zhi 2013; 15: 696-7. Chinese.  [<a href="/pubmed/23965889" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23965889</span></a>]</div></li><li><div class="bk_ref" id="Ceftriaxone.R71">Tomoda T, Ueki T, Saito S, Tatsukawa M, Nawa T, Hamamoto H, Endo H, et al. [A case of ceftriaxone-associated pseudolithiasis in an adult patient that disappeared after the discontinuation of ceftriaxone]. Nihon Shokakibyo Gakkai Zasshi 2013; 110: 1481-6. Japanese.  [<a href="/pubmed/23912008" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23912008</span></a>]<div><i>(47 year old woman found to have developed biliary stones and sludge on CT scan after 8 days of intravenous ceftriaxone, which disappeared within 6 days).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R72">von Martels JZ, Van de Meeberg EK, Holman M, Ligtenberg JJ, Ter Maaten JC. Pseudolithiasis after recent use of ceftriaxone: an unexpected diagnosis in a child with abdominal pain. Am J Emerg Med 2013; 31: 1294. e5-6.  [<a href="/pubmed/23809091" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23809091</span></a>]<div><i>(14 year old boy treated for Lyme disease with a 2 week course of iv ceftriaxone presented 4 days later with abdominal pain and biliary stones by ultrasound and ERCP [bilirubin 4.2 mg/dL, ALT 187 U/L, Alk P 398, GGT 291 U/L], resolving with conservative management within a few days and no stones found on follow-up ultrasound 4 weeks later).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R73">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A Chirino R, et al. Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. Ann Hepatol 2014; 13: 231-9.  [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i>(Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, but none were attributed to ceftriaxone or a cephalosporin).</i></div></div></li><li><div class="bk_ref" id="Ceftriaxone.R74">Alemayehu H, Desai AA, Thomas P, Sharp SW, St Peter SD. Ceftriaxone-induced pseudolithiasis in children treated for perforated appendicitis. Pediatr Surg Int 2014; 30: 323-6.  [<a href="/pubmed/24464035" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24464035</span></a>]<div><i> (Among 71 children treated with iv ceftriaxone for perforated appendicitis, 10 [14%] developed gallbladder stones or sludge, one of whom developed symptoms and underwent cholecystectomy).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548258</span><span class="label">PMID: <a href="/pubmed/31643582" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643582</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/CatsClaw/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Celandine/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548258&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548258/?report=reader">PubReader</a></li><li><a href="/books/NBK548258/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548258" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548258" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Ceftriaxone. [Updated 2014 May 5].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548258/pdf/Bookshelf_NBK548258.pdf">PDF version of this page</a> (163K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OHTER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=ceftriaxone/AE+AND+Human%5BMH%5D+AND+(jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI+OR+hepatitis,+toxic%5BMH%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Ceftriaxone: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=ceftriaxone" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Ceftriaxone: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4865692" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4865692" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4865692" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/16185184" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: case report and review of the literature.</a><span class="source">[Pharmacotherapy. 2005]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: case report and review of the literature.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bickford CL, Spencer AP. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Pharmacotherapy. 2005 Oct; 25(10):1389-95. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/19261600" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Implications of current recommendations for third-generation cephalosporin use in the WHO Western Pacific Region following the emergence of multiresistant gonococci.</a><span class="source">[Sex Transm Infect. 2009]</span><div class="brieflinkpop offscreen_noflow">Implications of current recommendations for third-generation cephalosporin use in the WHO Western Pacific Region following the emergence of multiresistant gonococci.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Tapsall JW. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Sex Transm Infect. 2009 Aug; 85(4):256-8. Epub 2009 Mar 3.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/10566187" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Acute cholecystitis and pancreatitis in a patient with biliary sludge associated with the use of ceftriaxone: a rare but potentially severe complication.</a><span class="source">[Ann Ital Med Int. 1999]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Acute cholecystitis and pancreatitis in a patient with biliary sludge associated with the use of ceftriaxone: a rare but potentially severe complication.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Famularo G, Polchi S, De Simone C. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Ann Ital Med Int. 1999 Jul-Sep; 14(3):202-4. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/2183609" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Safety of parenteral third-generation cephalosporins.</a><span class="source">[Am J Med. 1990]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Safety of parenteral third-generation cephalosporins.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Fekety FR. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Med. 1990 Apr 9; 88(4A):38S-44S. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/2227290" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility.</a><span class="source">[Gastroenterology. 1990]</span><div class="brieflinkpop offscreen_noflow">Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Shiffman ML, Keith FB, Moore EW. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Gastroenterology. 1990 Dec; 99(6):1772-8. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643582" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643582" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=60467b7a9e31203af64c3cb3">Ceftriaxone - LiverTox</a><div class="ralinkpop offscreen_noflow">Ceftriaxone - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T14:31:07-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal104&amp;ncbi_phid=CE8B31B104669E010000000003CA011A&amp;ncbi_session=CE8B31B10467B7A1_0970SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548258%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548258&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548258/&amp;ncbi_pagename=Ceftriaxone - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8B31B10467B7A1_0970SID /projects/books/PBooks@9.2 portal104 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>